Elliott Jeffrey Thomas's Form 4/A amendment
AmendedExact Sciences Corp (EXAS) · filed Aug 3, 2021
- Accession no.
- 0001209191-21-049201
- Filed
- Aug 3, 2021
- Trade date
- Apr 30-Jul 29, 2021
- Filing delay
- 95 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
- Original filed
- Aug 2, 2021
This filing lists 9 non-derivative transactions. Open-market sales total $4.27M. It was filed 95 days after the trade.
This amendment replaces 0001209191-21-049081 (filed Aug 2, 2021).
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Elliott Jeffrey ThomasCIK 0001689757 | Officer (Chief Financial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 30, 2021 | Common Stock | AGrant or awardAcquired | +206 | $103.22 | +$21,263.32 | 38,567 | Direct | |
| Jul 29, 2021 | Common Stock | SSaleDisposed | −1,200 | $107.54F2 | −$129,048 | 37,367 | Direct | |
| Jul 29, 2021 | Common Stock | SSaleDisposed | −1,066 | $108.54F3 | −$115,703.64 | 36,301 | Direct | |
| Jul 29, 2021 | Common Stock | SSaleDisposed | −2,602 | $109.58F4 | −$285,127.16 | 33,699 | Direct | |
| Jul 29, 2021 | Common Stock | SSaleDisposed | −7,818 | $110.64F5 | −$864,983.52 | 25,881 | Direct | |
| Jul 29, 2021 | Common Stock | SSaleDisposed | −13,853 | $111.58F6 | −$1,545,717.74 | 12,028 | Direct | |
| Jul 29, 2021 | Common Stock | SSaleDisposed | −8,675 | $112.39F7 | −$974,983.25 | 3,353 | Direct | |
| Jul 29, 2021 | Common Stock | SSaleDisposed | −1,899 | $113.35F8 | −$215,251.65 | 1,454 | Direct | |
| Jul 29, 2021 | Common Stock | SSaleDisposed | −1,248 | $114.41F9 | −$142,783.68 | 206 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The sale reported in this field was effected pursuant to a Rule 10b5-1 trading plan entered into in November 2020.
- F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.16 to $107.92, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.23 to $108.73, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote.
Referenced by the price of 1 transaction in Table I.
- F4
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.00 to $109.95, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote.
Referenced by the price of 1 transaction in Table I.
- F5
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.09 to $110.99, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote.
Referenced by the price of 1 transaction in Table I.
- F6
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.02 to $111.998, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote.
Referenced by the price of 1 transaction in Table I.
- F7
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.00 to $112.99, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote.
Referenced by the price of 1 transaction in Table I.
- F8
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.02 to $113.895, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote.
Referenced by the price of 1 transaction in Table I.
- F9
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.165 to $114.63, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote.
Referenced by the price of 1 transaction in Table I.
- F10
In addition to the shares of Common Stock reported on this Form 4, which total 1,396 shares, Mr. Elliott also holds, in the aggregate, an additional 135,562 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock.
Remarks
On August 2, 2021 the reporting person filed a Form 4 to report certain sales made pursuant to a Rule 10bb5-1 trading plan entered into in November 2020 (the "Trading Plan"). This Form 4/A is being filed solely to denote that the reported sales were made pursuant to the Trading Plan.